Alcon：業績表現、產品、產品線及未來發展潛力 是由出版商Espicom Business Intelligence在2010年02月所出版的。
這份英文市場調查報告書包含Pages: 52 價格從美金1040起跳。
Alcon公司是家主要開發製造並銷售治療眼睛疾病的藥物、外科設備及消費性產品的企業。總公司在瑞士的Alcon在全球75個以上的國家中擁有據點。該公司的產品在超過180個國家銷售。
提供製藥、醫療機器市場相關具有權威的資訊的市調公司 Espicom Business Intelligence（總公司：England），出版了一本關於Alcon公司的業績表現、產品、產品線及未來發展潛力的分析報告書"Alcon: Performance, Products, Pipeline and Potential"。
本報告書內容包括：該公司的介紹及主要產品銷售成績及預測、研發動向、與主要企業的合作趨勢等。內容綱要摘記如下：
實施概要
- 介紹
- 目前的財務狀況
- 企業策略
- 產品業績表現預測
- 產品線分析
- 其他影響利益的因素
- 結論／未來發展前景
治療領域
研發藥物產品線
眼科
耳科
附錄1：財務表現
附錄2：主要企業活動事件
附錄3：主要合作動向
附錄4：基礎環境建構
附錄5：主要子公司
附錄6：產品索引
圖表
Abstract
Alcon is a research and development-driven global company which develops,
manufactures and markets pharmaceuticals, surgical equipment and devices, and
consumer products to treat diseases and disorders of the eye. It has
operations in over 75 countries and its products are sold in over 180
countries. A subsidiary of Nestle, Alcon is a Swiss corporation.
On 7th April 2008, Novartis reached an agreement with Nestle providing the
right to acquire majority (77 per cent) ownership of Alcon in two steps. The
transaction' s first step, to purchase a 25 per cent stake in Alcon from Nestle
for US$143.18 per share, or US$10.4 billion, was completed in July 2008. The
optional second step provides Novartis with exclusive rights to acquire the
remaining 52 per cent Alcon stake held by Nestle between 1st January 2010 and
31st July 2011, for a fixed price of US$181 per share, totalling about US$28
billion; Nestle has the right to require Novartis to buy this stake. On 4th
January 2010, Novartis and Nestle initiated completion of the 2008 agreement.
If majority ownership is transferred from Nestle during the second step,
Novartis and Alcon will identify the best way to realise synergies from
combining their complementary eye-related businesses. Potential benefits could
include creating a broader portfolio of eye care products, in particular with
CIBA Vision' s contact lens business and Novartis medicines, such as Lucentis
(ranibizumab), for severe eye diseases not addressed by Alcon' s portfolio.
Other opportunities include research and development activities, and an even
more aggressive expansion in fast-growing regions, particularly Asia, where
Novartis has longstanding operations. In addition, the relationships of
Novartis with healthcare payers and strong health economics activities could
contribute to Alcon' s marketing programmes.
On the other side, Alcon would help limit risks within the Novartis portfolio
based on its diversified payor structure, with reduced risks of price
regulation, leadership in a specialty healthcare area and greater access to
businesses with discretionary consumer spending.
This new strategic analysis report Alcon: Pipeline - Products - Performance
- Potential, provides a complete and critical review of the company and
includes unique and independent assessments and forecasts of key products.
Buyers of the web edition receive online access for one year via an
easy-to-use interface with fast navigation and a full text search facility.
All formats are the same price.
Table of Contents
- Latest Results
- Merger News
- EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Segment Performance
- Company Strategy
- Key Agreements
- Acquisitions
- Product Performance Forecasts
- Pipeline Analysis
- Conclusions/Outlook
- THERAPEUTIC AREA FOCUS
- R&D PIPELINE
- OPHTHALMOLOGY
- Marketed Products
- Glaucoma
- Azarga
- Azopt
- DuoTrav
- Travatan
- Anti-infective/Anti-inflammatory
- Nevanac
- Rimexel
- TobraDex
- Vigamox/Vegamox
- Ocular Allergy
- Other
- R&D Projects
- AL-37807
- Cilomilast
- NVC-422
- POT-4
- Growth Forecast
- OTIC
- Marketed Products
- R&D Projects
- Growth Forecast
- APPENDIX 1 - FINANCIAL PERFORMANCE
- APPENDIX 2 - KEY CORPORATE EVENTS
- APPENDIX 3 - KEY AGREEMENTS
- Amgen
- AstraZeneca
- Dharmacon Inc.
- Eli Lilly
- GlaxoSmithKline
- Jerini AG
- Juvantia Pharma Ltd.
- Kalypsys Inc.
- Kyowa Hakko Kirin
- Lantibio Inc and TRB Chemedica Ltd.
- NovaBay Pharmaceuticals Inc.
- Origenis GmbH
- Potentia Pharmaceuticals Inc.
- Vernalis plc
- APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
- APPENDIX 5 - KEY PHARMACEUTICAL
- SUBSIDIARIES
- APPENDIX 6 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Sales By Business/Geographic Segment
- Operating Income By Segment
- Sales By Product Area
- Recent Product Approvals
- Major Therapeutic Areas And Sales
- Major Glaucoma Products, 2008
- Major Anti-infective/ Anti-inflammatory Products, 2008
- Major Ocular Allergy Products, 2008
INDEX OF CHARTS
- Sales By Segment, 2008
- Sales By Product Area, 2008
- Glaucoma Sales (2004A-2012E)
- Anti-infective/Anti-inflammatory Sales (2004A-2012E)
- Ocular Allergy Sales (2004A-2012E)
- Otic Sales (2004A-2012E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
